Fasinumab
Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | HNGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6406H9896N1700O2026S46 |
| Molar mass | 144618.27 g·mol−1 |
This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.
It is currently at Phase III trials.
See also
References
- "Fasinumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- Tiseo PJ, Ren H, Mellis S (2014). "Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study". Journal of Pain Research. 7: 523–30. doi:10.2147/JPR.S65974. PMC 4155988. PMID 25210473.
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bone ("-os-", "-s(o)-") |
| ||||||||
| Musculoskeletal ("-mul-") |
| ||||||||
| Circulatory ("-c(i[r])-") |
| ||||||||
| Neurologic ("-ne(u)(r)-") |
| ||||||||
| Angiogenesis inhibitor ("-anibi-") |
| ||||||||
| Growth factor ("-gr(o)-") |
| ||||||||
| |||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.